AnoopManayilNambiarMDMS, FCCP

Clinical Trials

• Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2008 Aug 01

  Completed

  Phase 3

• Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2011 Jun 01

  Completed

  Phase 3

• A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Oct 13

  Completed

  Phase 2

• Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone

  Approved for marketing

• Pulmonary Fibrosis Foundation Patient Registry Start of enrollment: 2016 Mar 29

  Completed

• CleanUP IPF for the Pulmonary Trials Cooperative Start of enrollment: 2017 Mar 22

  Terminated

  Phase 3

• Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial Start of enrollment: 2016 Dec 16

  Completed

  Phase 1

• Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial Start of enrollment: 2020 Dec 17

  Active, not recruiting

  Phase 3

  Roles: Contact

• JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF Start of enrollment: 2018 Jun 18

  Completed

  Phase 2

• A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis Start of enrollment: 2021 Mar 19

  Terminated

  Phase 3

• Pulmonary Fibrosis Foundation Community Registry Start of enrollment: 2022 Jul 11

  Recruiting

• Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Start of enrollment: 2017 Jan 17

  Completed

  Phase 3

• Join now to see all